# Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma

> **NCT05422027** · PHASE1,PHASE2 · RECRUITING · sponsor: **Xia Zhongjun** · enrollment: 42 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Selinexor
- **DRUG:** Bortezomib
- **DRUG:** Lenalidomide
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT05422027
- **Lead sponsor:** Xia Zhongjun
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-07-25
- **Primary completion:** 2025-06-30
- **Final completion:** 2025-12-31
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2024-06-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05422027

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05422027, "Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05422027. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*